DUBLIN–(BUSINESS WIRE)–The “Hemophilia Treatment Market By Type, By Drug Therapy: Global Opportunity Analysis and Industry Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.
The global hemophilia treatment market was valued at $12,764.8 million in 2021, and is projected to reach $26,905.2 million by 2031, registering a CAGR of 7.5% from 2022 to 2031.
Hemophilia is usually an inherited bleeding disorder, in which the blood does not clot properly. This can lead to spontaneous bleeding, followed by injuries or surgery. Blood contains many proteins called clotting factors, which can help stop the bleeding.
People with hemophilia have low levels of factor VIII or factor IX. The severity of hemophilia that a person has is determined by the amount of factor in the blood. Hemophilia is caused by a mutation or change in one of the genes that provides instructions for making the clotting factor proteins needed to form a blood clot.
There are two major types of hemophilia, namely hemophilia A and hemophilia B. The treatment of hemophilia involves replacement of missing blood clotting factor so that the blood can clot properly. This is done by infusion, in which the commercially prepared factor concentrates are administered through a vein. People with hemophilia can learn how to perform these infusions themselves so that they can stop bleeding episodes and, by performing the infusions on a regular basis can even prevent most bleeding episodes.
The major factors that drive the growth of the global hemophilia treatment market include: increase in the prevalence of hemophilia, technological advancements in the treatment of hemophilia, and favorable government initiatives for hemophilia management. In addition, increase in target population, increased diagnosis rate, and rise in the use of prophylactic treatment for hemophilia also propel the market growth.
However, high cost of hemophilia treatment, lack of medicines of hemophilia, and serious adverse effects associated with plasma derived products are expected to restrict the market growth. Conversely, the rise in the awareness about hemophilia in developing countries provides lucrative opportunities for the growth of the market.
Key Benefits
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemophilia treatment market analysis from 2021 to 2031 to identify the prevailing hemophilia treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hemophilia treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hemophilia treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Hemophilia A
Hemophilia B
By Drug Therapy
Recombinant coagulation factor concentrates therapy
Plasma derived coagulation factor concentrates therapy
Non-factor replacement therapy
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Bayer AG
CSL Ltd. (CSL Behring)
F. Hoffmann-La Roche AG
Grifols, S.A
Medexus Pharmaceuticals Inc.
Novo Nordisk A/S
octapharma ag
Pfizer Inc.
Swedish Orphan Biovitrum AB
Takeda Pharmaceuticals Company Ltd
For more information about this report visit https://www.researchandmarkets.com/r/uvwgw9
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
